Renewal of Provisional Consent to the Distribution of a New Medicine Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto: Schedule Product: Bretylium Tosylate. Active Ingredient(s): Bretylium tosylate 50 mg/mL. Dosage Form: Solution for injection. NZ Sponsor: Abbott Laboratories (NZ) Limited. Manufacturer(s): Abbott Laboratories, Rocky Mount, North Carolina, United States of America. Note: This consent is valid for 2 years from 30 October 1999. Product: Viramune. Active Ingredient(s): Nevirapine 200 mg. Dosage Form: Tablet. NZ Sponsor: Boehringer Ingelheim (NZ) Limited. Manufacturer(s): Boehringer Ingelheim Pharmaceuticals Inc, Danbury, Connecticut, United States of America. Roxane Laboratories Inc, Columbus, Ohio, United States of America. Note: This consent is valid for 2 years from 4 December 1999. Dated this 1st day of December 1999. S. S. JESSAMINE, Acting Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).